Dana E Rathkopf, Michael J Morris, Josef J Fox, Daniel C Danila, Susan F Slovin, Jeffrey H Hager, Peter J Rix, Edna Chow Maneval, Isan Chen, Mithat Gönen, Martin Fleisher, Steven M Larson, Charles L Sawyers, Howard I Scher
PURPOSE: ARN-509 is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC). ARN-509 inhibits AR nuclear translocation and AR binding to androgen response elements and, unlike bicalutamide, does not exhibit agonist properties in the context of AR overexpression. This first-in-human phase I study assessed safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of ARN-509 in men with metastatic CRPC. PATIENTS AND METHODS: Thirty patients with progressive CRPC received continuous daily oral ARN-509 at doses between 30 and 480 mg, preceded by administration of a single dose followed by a 1-week observation period with pharmacokinetic sampling...
October 1, 2013: Journal of Clinical Oncology